Prevention & lipidsResearch article
Lipoprotein(a)-lowering therapies: a promising future
- Narrative review
Study context
- Population
- Patients with elevated Lp(a)
Main finding
As reported in the abstract
Lp(a) lowering with emerging Lp(a)-targeted therapies (narrative review)
- Current lipid-lowering agents and lifestyle interventions have minimal impact on lowering Lp(a); lipoprotein apheresis is the sole effective but impractical method
- Antisense oligonucleotides, small interfering RNAs and a small-molecule inhibitor of Lp(a) synthesis showed substantial, often durable Lp(a) lowering in Phase II trials
- Phase III trials of these agents on atherosclerotic cardiovascular disease (ASCVD) outcomes are underway
Original publication
Lipoprotein(a)-lowering therapies: a promising future. Eur Heart J. Published 13 February 2026. doi:10.1093/eurheartj/ehag092
Summarised from the published abstract; every number is checked against it